| Company Name: | Illumina Incorporated | | Ticker Symbol: | ILMN | | | WWW Address: | www.illumina.com | | CEO: | Jay T. Flatley | | No. of Employees: | 1,536 | | Common Issue Type: | CS | | Business Description: | The company is developer, manufacturer and marketer of integrated systems for the large scale analysis of genetic variation and biological function.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 28.78 |  0.79 | 28.77 | 28.78 | 28.17 | 28.15 | 26.20 | 4508459 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 3,600.4 | 125.1 | 0.68 | 0.38 | 0.00 | 42.4 | 0.0 | 44.07 - 19.49 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 27.99 | $ | | PE Ratio - LTM | 42.4 | |
| Market Capitalisation | 3,501.3 | mil |
| Latest Shares Outstanding | 125.1 | mil |
| Earnings pS (EPS) | 0.38 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 373,193 | $ |
| Effective Tax Rate | 44.5 | % |
| Float | 122.7 | mil |
| Float as % of Shares Outstanding | 98.8 | % |
| Foreign Sales | 293 | mil |
| Domestic Sales | 280 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 25.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 19.90 | % |
| Gross Profit Margin | 74.2 | % |
| EBITDA Margin | 28.6 | % |
| Pre-Tax Profit Margin | 20.3 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | 5.8 | % |
| Return on Equity (ROE) | 8.9 | % |
| Return on Capital Invested (ROCI) | 8.9 | % |
| Current Ratio | 2.5 | |
| Leverage Ratio (Assets/Equity) | 1.5 | |
| Interest Cover | 14.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.28 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 4.95 | $ |
| Cash pS | 1.91 | $ |
| Book-Value pS | 8.01 | $ |
| Tangible Book-Value pS | 5.84 | $ |
| Cash Flow pS | 1.10 | $ |
| Free Cash Flow pS | 0.81 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.49 | |
| Price/Tangible Book Ratio | 4.79 | |
| Price/Cash Flow | 25.5 | |
| Price/Free Cash Flow | 34.6 | |
| P/E as % of Industry Group | 189.0 | % |
| P/E as % of Sector Segment | 31.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 4.4 | 103 | 43,849 | 134,804 |
| 4 Weeks | 33.55 | 25.59 | 32.10 | -12.8 | 82 | 33,447 | 568,604 |
| 13 Weeks | 44.07 | 25.59 | 35.25 | -20.6 | 74 | 24,960 | 1,522,560 |
| 26 Weeks | 44.07 | 25.59 | 36.71 | -23.8 | 63 | 20,607 | 2,575,915 |
| 52 Weeks | 44.07 | 19.49 | 22.01 | 27.2 | 103 | 19,980 | 4,975,013 |
| YTD | 44.07 | 23.29 | - | 7.4 | 88 | 20,500 | 4,653,530 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 27.74 | 30.10 | 37.47 | 36.59 | 36.16 | 0.68 | 0.50 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 73.54 | 95.5 | 53.16 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 44.69 | NA | 54.42 |
| Normalized Inc. | 0.00 | NA | 22.01 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 17.8 | 5.4 | 56.3 |
| Earnings % | 181.3 | 0.0 | 0.0 |
| EPS % | 175.0 | 0.0 | 0.0 |
| EPS $ | 0.28 | 0.18 | 2.95 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 25.81 |
| Current Ratio | 1.7 |
| Quick Ratio (Acid Test) | 1.5 |
| Liquidity Ratio (Cash) | 1.26 |
| Receivables Turnover | 5.3 |
| Average Collection Period | 68 |
| Working Capital/Equity | 41.9 |
| Working Capital pS | 2.94 |
| Cash-Flow pS | 0.66 |
| Free Cash-Flow pS | -0.27 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 4.96 |
| Financial Leverage Ratio (Assets/Equity) | 1.6 |
| Debt Ratio | 38.4 |
| Total Debt/Equity (Gearing Ratio) | 0.47 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 2.2 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 44.9 |
| Interest/Capital Invested | 0.24 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 6.40 |
| Tobin's Q Ratio | 2.54 |
| Current P/E Ratio - LTM | 42.40 |
| Enterprise Value (EV)/EBITDA | 24.54 |
| Enterprise Value (EV)/Free Cash Flow | -105.75 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 4.79 |
| Price/Book Ratio - LTM | 3.49 |
| Price/Cash Flow Ratio | 25.5 |
| Price/Free Cash Flow Ratio - LTM | 34.6 |
| Price/Sales Ratio | 5.41 |
| P/E Ratio (1 month ago) - LTM | 61.9 |
| P/E Ratio (26 weeks ago) - LTM | 87.4 |
| P/E Ratio (52 weeks ago) - LTM | 157.2 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 189.0 |
| P/E as % of Sector Segment | 31.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 41.8 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 4.21 |
| Tangible Book Value pS - LTM | 5.84 |
| Book Value pS - LTM | 8.01 |
| Capital Invested pS | 6.78 |
| Cash pS - LTM | 1.91 |
| Cash Flow pS - LTM | 1.10 |
| Free Cash Flow pS - LTM | 0.81 |
| Earnings pS (EPS) | 0.38 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -5.67 |
| Free Cash Flow Margin 5YEAR AVG | -13.57 |
| Net Profit Margin | 8.8 |
| Net Profit Margin - 5YEAR AVRG. | -17.2 |
| Equity Productivity | 0.68 |
| Return on Equity (ROE) | 5.9 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.68 |
| Return on Capital Invested (ROCI) | 5.9 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -10.5 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | 3.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | -7.5 |
| Gross Profit Margin | 74.2 |
| Gross Profit Margin - 5YEAR AVRG. | 68.9 |
| EBITDA Margin - LTM | 28.6 |
| EBIT Margin - LTM | 21.9 |
| Pre-Tax Profit Margin | 15.9 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -14.6 |
| Effective Tax Rate | 44.5 |
| Effective Tax Rate - 5YEAR AVRG. | 10.9 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 207 |
| Revenue per Employee | 373,193 |
| Net Income per Employee | 32,863 |
| Average Collection Period | 84 |
| Receivables Turnover | 5.3 |
| Day's Inventory Turnover Ratio | 123 |
| Inventory Turnover | 2.9 |
| Inventory/Sales | 12.8 |
| Accounts Payble/Sales | 5.09 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 1.61 |
| Fixed Assets Turnover | 1.12 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 1.75 |
| Revenue per $ Plant | 6.41 |
| Revenue per $ Common Equity | 0.68 |
| Revenue per $ Capital Invested | 0.68 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 25.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 28.5 |
| Research & Devlopment (R&D) as % of Revenue | 17.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 17.4 |
|
|  
|
| |
 |  |